Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

409

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

July 30, 2027

Conditions
Prostate Cancer Metastatic
Interventions
RADIATION

Ablative Radiation Therapy

Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).

OTHER

Standard of care

Patients continue to receive their current planned systemic therapy at the discretion of the treating physician

Trial Locations (18)

V8R 6V5

BCCA - Victoria, Victoria

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 1V7

QEII Health Sciences Centre, Halifax

L4M 6M2

Royal Victoria Regional Health Centre, Barrie

P3E 5J1

Health Sciences North, Greater Sudbury

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

Kingston Health Sciences Centre, Kingston

L5M 2N1

Trillium Health Partners - Credit Valley Hospital, Mississauga

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

P6B 0A8

Algoma District Cancer Program, Sault Ste. Marie

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

University Health Network, Toronto

H1T 2M4

CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal

H2X 3E4

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

H3T 1E2

The Jewish General Hospital, Montreal

G1R 2J6

Hotel-Dieu de Quebec, Québec

S4T 7T1

Allan Blair Cancer Centre, Regina

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

All Listed Sponsors
collaborator

Canadian Cancer Society (CCS)

OTHER

lead

Canadian Cancer Trials Group

NETWORK